Q-omics provides the consensus-scored BRD7 profile across patient tissues and cancer cell-line models. BRD7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BRD7 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, BRD7 protein abundance shows 25,104 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where BRD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRD7 survival associations across molecular data types. BRD7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRD7 RNA expression–survival associations across cancer types. High BRD7 expression shows unfavorable associations in LUSC and BLCA, but favorable associations in KIRC, UCEC, THYM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BRD7 RNA expression.
This table summarizes BRD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BRD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRD7 shows higher tumor expression in HNSC, LIHC, BLCA, KIRP, CHOL and STAD. The HNSC box plot shows higher BRD7 RNA expression in tumor versus normal tissue (log2 FC = +0.467, t-test p < 0.001).
This table shows molecular features associated with BRD7 in patient tissues and cancer cell lines. In patient samples, BRD7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BRD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
